Pesquisa de medicamentos por nome

Nimotop e CHF / AMI

Resultado da verificação da interação do medicamento Nimotop com doença CHF / AMI quanto a segurança no uso em conjunto.

Resultado da verificação:

Nimotop <> CHF / AMI

Relevância: 23.07.2019 Revisor: Shkutko P.M., M.D., in

Na verificação da interação, conforme informações das fontes confiáveis como Drugs.com, Rxlist.com, Webmd.com, Medscape.com, foram identificadas as contra-indicações ou efeitos colaterais que podem prejudicar a saúde ou aumentar efeito negativo ao consumir o medicamento com esta doença concomitante.

Consumidor:

Bloqueadores dos canais de cálcio (CCBs) pode ter vários graus de efeito inotrópico negativo. Insuficiência cardíaca congestiva (ICC), agravamento de insuficiência cardíaca congestiva e edema pulmonar ocorreram em alguns pacientes tratados com a CCB, principalmente verapamil. Alguns CCBs também tem causado leve a moderada, edema periférico, devido à vasodilatação localizada de dependentes arteríolas e pequenos vasos sanguíneos, o que pode ser confundido com os efeitos do aumento da disfunção ventricular esquerda. Apesar de alguns CCBs têm sido utilizados no tratamento da ICC, a terapia com CCBs deve ser administrado com cautela em pacientes com grave disfunção ventricular esquerda (por exemplo, fração de ejeção < 30%) ou sintomas moderados a graves de insuficiência cardíaca e em pacientes com qualquer grau de disfunção ventricular se eles estão recebendo um beta-adrenérgicos, bloqueadores. Da mesma forma, recomenda-se precaução em pacientes com infarto agudo do miocárdio e congestão pulmonar documentada por um raio-X de admissão, desde que associado a insuficiência cardíaca pode ser aguda, agravada pela administração do CCB.

Referências

Batlouni M, Armaganijan D, Ghorayeb N, Magliano MF "Clinical efficacy and tolerability of isradipine in the treatment of mild-to-moderate hypertension in young and elderly patients." J Cardiovasc Pharmacol 19 (1992): s53-7
"Product Information. Procardia (nifedipine)." Pfizer US Pharmaceuticals, New York, NY.
Fagan TC, Haggert BE, Liss C "Efficacy and tolerability of extended-release felodipine and extended-release nifedipine in patients with mild-to-moderate essential hypertension." Clin Ther 16 (1994): 634-46
Sleight P "Calcium antagonists during and after myocardial infarction." Drugs 51 (1996): 216-25
Brogden RN, Sorkin EM "Isradipine: an update of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of mild to moderate hypertension." Drugs 49 (1995): 618-49
Batra AK, Segall PH, Ahmed T "Pulmonary edema with nifedipine in primary pulmonary hypertension." Respiration 47 (1985): 161-3
Elkayam U "Calcium channel blockers in heart failure." Cardiology 89 (1998): 38-46
Prigogine T, Waterlot Y, Gottignies P, et al "Acute nonhemodynamic pulmonary edema with nifedipine in primary pulmonary hypertension." Chest 100 (1991): 563-4
Kubota K, Pearce GL, Inman WHW "Vasodilation-related adverse events in diltiazem and dihydropyridine calcium antagonists studied by prescription-event monitoring." Eur J Clin Pharmacol 48 (1995): 1-7
"Product Information. Norvasc (amlodipine)." Pfizer US Pharmaceuticals, New York, NY.
Lorimer AR, Pringle SD "The safety of felodipine." J Cardiovasc Pharmacol 15 (1990): s85-9
Myrhed M, Wiholm B-E "Nifedipine: a survey of adverse effects." Acta Pharmacol Toxicol (Copenh) 58 (1986): 133-6
Yedinak KC, Lopez LM "Felodipine: a new dihydropyridine calcium-channel antagonist." DICP 25 (1991): 1193-206
Taylor SH, Frais MA, Lee P, Verma SP, Jackson N, Reynolds G, Silke B "A study of the long-term efficacy and tolerability of oral nicardipine in hypertensive patients." Br J Clin Pharmacol 20 (1985): s139-42
Sundstedt CD, Ruegg PC, Keller A, Waite R "A multicenter evaluation of the safety, tolerability, and efficacy of isradipine in the treatment of essential hypertension." Am J Med 86 (1989): 98-102
"Product Information. Sular (nisoldipine)." Zeneca Pharmaceuticals, Wilmington, DE.
Blecker D "Antihypertensive therapy with isradipine in patients with special safety concerns." Angiology 45 (1994): 997-1008
Johnson BF, Eisner GM, Mcmahon FG, Jain AK, Rudd P, Sowers JR "A multicenter comparison of adverse reaction profiles of isradipine and enalapril at equipotent doses in patients with essential hypertension." J Clin Pharmacol 35 (1995): 484-92
Dubois C, Blanchard D "Efficacy and safety of nicardipine in 29,104 patients with hypertension." Clin Ther 11 (1989): 452-60
"Product Information. Cardene (nicardipine)." Syntex Laboratories Inc, Palo Alto, CA.
Gillmer DJ, Kark P "Pulmonary oedema precipitated by nifedipine." Br Med J 280 (1980): 1420-1
Walton T, Symes LR "Felodipine and isradipine: new calcium-channel-blocking agents for the treatment of hypertension." Clin Pharm 12 (1993): 261-75
"Product Information. DynaCirc (isradipine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.
Scheidt S, LeWinter MM, Hermanovich J, Venkataraman K, Freedman D "Efficacy and safety of nicardipine for chronic, stable angina pectoris: a multicenter randomized trial." Am J Cardiol 58 (1986): 715-21
Schaefer RM, Aldons PM, Burgess ED, Tilvis R, Singh GP, Rehn L, Morgan TO "Improved tolerability of felodipine compared with amlodipine in elderly hypertensives: A randomised, double-blind study in 535 patients, focusing on vasodilatory adverse events." Int J Clin Pract 52 (1998): 381
"Product Information. Plendil (felodipine)." Merck & Co, Inc, West Point, PA.
Abernathy DR, Schwrtz JB "Calcium-antagonist drugs." N Engl J Med 341 (1999): 1447-57
Ruegg PC, Nelson DJ "Safety and efficacy of isradipine, alone and in combination, in the treatment of angina pectoris." Am J Med 86 (1989): 70-4
"Product Information. Nimotop (nimodipine)." Bayer, West Haven, CT.